ArgenTAG

ArgenTAG is building a next-generation single-cell sequencing technology. They developed a novel approach for researchers, biotech and pharma companies to reveal the complete RNA landscape of cells in a cost-effective and scalable way. It's based on a device-free protocol and a proprietary barcoding technology for long-read DNA sequencers. The company is located in New York City (US) where they are running collaborations with well-known academic institutions and biotech companies. They also have a R&D center in Rosario (Argentina). They recently completed IndieBio, #1 biotech acceleration program, and gained SOSV, DraperU Ventures and Grid Exponential as investors.